Black Women Prescribed Menopausal Hormone Therapy at Significantly Lower Rates Despite More Severe Symptoms, Study Finds
TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.
Age, Not Menopause Stage, Drives Cortical Volume Reduction in Midlife Women, New Study Suggests
TMS: Findings from a large study presented at TMS 2025 counter previous reports suggesting menopause-specific effects on brain structure at midlife.
Study Finds Atypical MI Causes More Frequent in Women Aged Under 65: Daily Dose
Your daily dose of the clinical news you may have missed.
New Large-Scale Study Challenges Previous Research on Menopause and Brain Structure
New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.
Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research
TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks
Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.
Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Eligibility Test for DMT in Alzheimer Disease
Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.
Provider Specialty and Type Drive Divergent Prescribing Patterns for Symptoms of Menopause
TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.
6 Latent Menopausal Phenotypes Identified by Machine Learning in 10-Year SWAN Follow-Up
TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.
Orforglipron Achieves Up to 12% Weight Loss in Obesity Phase 3 Study: Daily Dose
The Only Predictable Thing About Perimenopause Is Unpredictability, Says Dr Marla Shapiro
TMS 2025. University of Toronto professor Dr Marla Shapiro explains why perimenopause is unpredictable, including age of onset, duration, and symptoms.
Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk
The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.
FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps
Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.
Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission
GRAIL's PATHFINDER 2 study shows Galleri blood test detected 7 times more cancers when added to standard screenings, with 99.6% specificity and low false positives.
Most Parents Support Childhood Vaccines, But Doubt Flu and COVID-19 Shots: Daily Dose
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
Vaccine-preventable diseases claim up to 50,000 adult lives each year in the US. Click through this compact reminder of recommended catch up shots for your patient panel.
Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...
Undertreated acute pain can lead to life-long chronic pain but there are still few effective opioid-sparing options. A new review reinforces the persistent safety issues.
Diagnosing DVT: Clinical Pearls for Challenging Presentations
A family medicine physician shares a case of massive PE presenting as syncope and explains the history questions that prevent missed DVT diagnoses in primary care.
Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD
Primary care physicians enhance early detection and management of vascular diseases, emphasizing patient history, screening, and strong relationships for better outcomes.
New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive
The survey of more than 19,000 American women found low energy and sleep problems more disruptive than VMS and that Autumn is the most symptomatic season.
Survey Finds Semaglutide Eases Food-Related Intrusive Thoughts, Boosts Mental Health: Daily Dose
Obesity Still Plagues the US, But Rates Are Declining in Some States: The Trust for America's Health Report
Obesity rates in states where it has leveled at 35% decreased for the first time but report authors warn the progress is limited and at risk due to federal budget cuts.
Multidisciplinary Lung Cancer Screening Program Achieves Screening Rates Above 70%
A multidisciplinary lung cancer screening program significantly boosts screening rates, ensuring timely follow-ups and early diagnoses for eligible patients.
Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose
Practical Takeaways from FMX 2025: What Every Family Physician Should Know
FMX 2025 highlights for primary care include expert insights on vaccine confidence, chronic cough management, and vascular disease prevention.
Abdominal Aortic Aneurysm Management: From Detection to Referral and Ongoing Surveillance
Highlights include size-based surveillance protocols, referral timing, cardiovascular risk reduction, and coordination with vascular surgery.
Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials
Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.
Benzodiazepine, Antipsychotic Use Linked to Increased Mortality in Hospice Patients With Dementia
A study reveals that starting benzodiazepines or antipsychotics in hospice patients with dementia significantly increases 180-day mortality, urging careful prescribing.
Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D
GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.
Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials
Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.
